Indicaton

SeaGen's lead product ADCETRIS® (brentuximab vedotin) is marketed in over 70 countries worldwide for the treatment of CD30-expressing lymphomas, in collaboration with Takeda Pharmaceutical Company Limited.

Therapeutic indications
Type of product
Table
  • Phase

    Marketed

  • Partnering status

    Partnered

  • Partner

    Takeda Pharmaceutical Company Limited.

  • Available in

    EU, US, LATAM, JAPAC, Switzerland